With the recent clinical validation by BMS, LAG-3 combinations are spearheading the next wave of immune checkpoint inhibitors. As such, there has been an explosion of interest and high-scale investment into this exciting space.
Arriving at a critical point for LAG-3 development, the first ever LAG-3 Targeted Drug Development Summit is the definitive industry-led event focused on propelling this next generation inhibitor to clinical use.
Ensure your LAG-3 program reaches full clinical potential through hearing from experts discuss:
The progress that has been made and challenges faced in bispecific antibody based approaches
Improving combination therapy regimens
Better understanding the underpinning biology of LAG-3 as a cancer target
Utilizing biomarkers to understand the interplay between PD-1 and LAG-3
Join translational and clinical experts in LAG-3 development from Roche, BMS, F-STAR, Regeneron, Immutep, Macrogenics, University of Pittsburgh and more.
Arriving at a critical point for LAG-3 development, the first ever LAG-3 Targeted Drug Development Summit is the definitive industry-led event focused on propelling this next generation inhibitor to clinical use.
Ensure your LAG-3 program reaches full clinical potential through hearing from experts discuss:
The progress that has been made and challenges faced in bispecific antibody based approaches
Improving combination therapy regimens
Better understanding the underpinning biology of LAG-3 as a cancer target
Utilizing biomarkers to understand the interplay between PD-1 and LAG-3
Join translational and clinical experts in LAG-3 development from Roche, BMS, F-STAR, Regeneron, Immutep, Macrogenics, University of Pittsburgh and more.
